On April 6, 2021 Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, reported that Dr. Jennifer Buell, President and COO, Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery, at Agenus, will participate in a webcast hosted by Dr. Matt Phipps of William Blair on Saturday, April 10, 2021 at 10:30 a.m. ET (Press release, Agenus, APR 6, 2021, View Source [SID1234577631]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Steven O’Day will review abstracts presented at AACR (Free AACR Whitepaper) 2021 featuring AGEN1181 and balstilimab, including objective responses observed in the ongoing Phase 1/2 trial, clinical benefits seen in underserved patient populations, and how they may inform the path forward for continued development.
Dr. Jennifer Buell and Dr. Dhan Chand will also be available to discuss the Fc-engineering driving AGEN1181’s enhanced activity, and how the AACR (Free AACR Whitepaper) presentations support AGEN1181’s place in the Agenus pipeline, alone and in combination with other immune-focused anti-cancer mechanisms.
Registration for the webinar can be done in advance at View Source
A replay will be available after the call on the Events & Presentations page of the Agenus website at View Source